Observational Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. May 7, 2021; 27(17): 2039-2053
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.2039
Table 4 Descriptive visual analogue scale score for patient groups with/without hypophosphatemia independent of treatment group
VAS item
Normal phosphate group, baseline, mean ± SD
Hypophosphatemia group, baseline, mean ± SD
Difference1 at baseline, mean (95%CI)
P value
Normal phosphate group, change at week 2, mean ± SD
Hypophosphatemia group, change at week 2, mean ± SD
Difference1 at week 2, mean (95%CI)
P value
Normal phosphate group, change at week 6, mean ± SD
Hypophosphatemia group, change at week 6, mean ± SD
Difference1 at week 6, mean (95%CI)
P value
General weakness43.54 ± 28.731.17 ± 30.512.4 (-7.6 to 32.4)0.205-4.98 ± 14.9-1.50 ± 17.2-3.5 (-14.7 to 7.7)0.515-10.64 ± 21.9)-6.33 ± 25.7-4.3 (-21.1 to 12.5)0.589
Fatigue37.53 ± 30.029.58 ± 30.17.9 (-11.8 to 27.7)0.403-3.31 ± 19.4-1.33 ± 17.9-2.0 (-13.9 to 9.9)0.728-8.93 ± 22.0-5.17 ± 26.7-3.8 (-21.2 to 13.6)0.648
Joint pain17.30 ± 23.38.25 ± 14.89.1 (-1.2 to 19.3)0.0810.32 ± 14.3-3.09 ± 6.93.4 (-1.9 to 8.7)0.1972.17 ± 18.00.17 ± 7.42.0 (-3.8 to 7.8)0..489
Joint stiffness13.31 ± 22.31.42 ± 3.411.9 (6.9 to 16.8)< 0.001-0.57 ± 18.1-0.64 (2.1)0.1 (-3.9 to 4.0)0.9720.99 ± 17.71.75 ± 8.5-0.8 (-7.1 to 5.6)0.807
Muscle pain15.35 ± 23.15.83 ± 14.59.5 (-0.5 to 19.6)0.062-1.71 ± 14.62.45 (8.9)-4.2 (-10.7 to 2.3)0.194-0.50 ± 20.6-0.17 ± 11.0-0.3 (-8.3 to 7.6)0.932
Bone and skeletal pain7.24 ± 19.41.92 ± 6.65.3 (-0.3 to 10.9)0.0611.85 ± 20.22.64 (8.7)-0.8 (-7.7 to 6.1)0.8173.42 ± 18.7-1.67 ± 6.85.1 (-0.5 to 10.7)0.076
Difficulties performing daily activities34.38 ± 28.529.67 ± 29.74.7 (-14.8 to 24.2)0.611-3.80 ± 14.9-2.17 (23.5)-1.6 (-16.8 to 13.5)0.819-9.45 ± 20.0-11.00 ± 24.81.6 (-14.6 to 17.7)0.839